Vaxcyte (PCVX) risk factors, FY2025 10-K

Risks Related to Our Financial Position and Capital Needs

1. 01We are in the clinical or preclinical stages of vaccine development and have a limited operating history and no products approved for commercial sale, which may make it difficult for you to evaluate the success of our business to date and to assess our future viability
2. 02We will require substantial additional funding to finance our operations, which may not be available to us on acceptable terms, or at all. If we are unable to raise additional capital when needed, we could be forced to delay, reduce or terminate certain of our development programs or other operations44% rewritten

Risks Related to Our Business and Industry

1. 03In addition, changes to the standard-of-care or the approval standards for new vaccines have, and could again in the future, change the threshold for achievement of non-inferiority using the established surrogate immune endpoints that our PCVs will need to meet in our clinical trialsNew
2. 04Our inability to complete development of or commercialize our vaccine candidates, or significant delays in doing so due to one or more of these factors, could have a material and adverse effect on our business, financial condition, results of operations and prospects
3. 05Our business is highly dependent on the success of our PCV candidates. If we are unable to successfully develop, obtain approval for and effectively commercialize our PCV candidates, our business would be significantly harmed
4. 06Our primary competitors have significantly greater resources and experience than we do, which may make it difficult for us to successfully develop and commercialize our vaccine candidates, or may result in others discovering, developing or commercializing products before or more successfully than us32% rewritten
5. 07We and our contract manufacturers may face difficulty satisfying CMC requirements imposed by the FDA and comparable foreign regulatory authorities. To date, no product developed using a cell-free manufacturing platform has received approval from the FDA or been commercialized
6. 08Even if we obtain regulatory approval of our vaccine candidates, the products may not gain market acceptance among regulators, advisory boards, physicians, patients, third-party payors and others in the medical community necessary for commercial success62% rewritten
7. 09We may not be successful in our efforts to use our cell-free protein synthesis platform to expand our pipeline of vaccine candidates and develop marketable products56% rewritten
8. 10Our vaccine candidates may cause undesirable side effects or have other properties, including interactions with existing vaccine regimens, that could halt their clinical development, prevent their regulatory approval, limit their commercial potential or result in significant negative consequences
9. 11Negative developments and negative public opinion of vaccines or new technologies on which we rely may damage public perception of our vaccine candidates or adversely affect our ability to conduct our business or obtain regulatory approvals for our vaccine candidates39% rewritten
10. 12We may not be able to file IND applications to commence clinical trials on the timelines we expect, and even if we are able to, the FDA may not permit us to proceed
11. 13We may encounter substantial delays in our clinical trials or may not be able to conduct our trials on the timelines we expect
12. 14If we encounter difficulties enrolling subjects in any clinical trials we may conduct, including any field efficacy trials that may be required, our clinical development activities could be delayed or otherwise adversely affected38% rewritten
13. 15Interim topline and preliminary data from our clinical trials that we announce or publish from time to time may change as more patient data become available and are subject to audit and verification procedures that could result in material changes in the final data
14. 16We currently have no marketing and sales organization, and as an organization have no experience in marketing products. If we are unable to establish marketing and sales capabilities or enter into agreements with third parties to market and sell our vaccine candidates, we may not be able to generate product revenue
15. 17A variety of risks associated with our current and potential international operations and collaborations could materially adversely affect our businessNew
16. 18We are highly dependent on our key personnel, and if we are not able to retain these members of our management team or recruit and retain highly qualified personnel, we may not be able to successfully implement our business strategy
17. 19We have grown rapidly and will need to continue to grow the size of our organization, and we may experience difficulties in managing this growth36% rewritten
18. 20attention away from day-to-day activities in order to devote a substantial amount of time to managing these growth activitiesNew
19. 21Obtaining and maintaining regulatory approval of our vaccine candidates in one jurisdiction does not mean that we will be successful in obtaining regulatory approval of our vaccine candidates in other jurisdictions
20. 22We may form or seek strategic alliances or enter into additional licensing arrangements in the future, and we may not realize the benefits of such alliances or licensing arrangements
21. 23Revenue from any “catch up” opportunity may decline over time as more of the patient population is vaccinated69% rewritten
22. 24or other liability; regulatory investigations or actions; disruptions of our development programs or business operations; harms to our reputation; and other adverse consequencesNew
23. 25Use of artificial intelligence in our operations could result in reputational or competitive harm and legal or regulatory liability44% rewritten
24. 26AI becomes controversial, we may experience brand or reputational harm, competitive harm, regulatory scrutiny or legal liability. In addition, use of personal data in generative AI technologies is subject to various privacy laws and other privacy obligationsNew
25. 27Natural or man-made disasters or business disruptions could seriously harm our future revenue and financial condition and increase our costs and expenses59% rewritten
26. 28If product liability lawsuits are brought against us, we may incur substantial liabilities and may be required to limit commercialization of our vaccine candidates
27. 29Our employees, principal investigators, consultants and commercial partners may engage in misconduct or other improper activities, including noncompliance with regulatory standards and requirements and insider trading
28. 30Changes in tax laws or tax rulings could affect our financial position99% rewritten
29. 31Our ability to utilize our net operating loss ("NOL") carryforwards and certain other tax attributes may be limited31% rewritten
30. 32Our insurance policies may be inadequate and potentially expose us to unrecoverable risks

Risks Related to Our Reliance on Third Parties

1. 33We rely and will continue to rely on third parties to conduct our preclinical studies and clinical trials. If these third parties do not successfully carry out their contractual duties or meet expected deadlines, we may not be able to obtain regulatory approval of or commercialize our vaccine candidates41% rewritten
2. 34We have not yet caused our vaccine candidates to be manufactured on a commercial scale and may not be able to achieve commercial scale manufacturing and may be unable to create an inventory of mass-produced product to satisfy demands for any of our vaccine candidates
3. 35If we or our third-party suppliers use hazardous, non-hazardous, biological or other materials in a manner that causes injury or violates applicable law, we may be liable for damages

Risks Related to Government Regulation

1. 36The FDA regulatory approval process is lengthy and time-consuming, and we may experience significant delays in the clinical development and regulatory approval of our vaccine candidates
2. 37The FDA may disagree with our regulatory plan, and we may fail to obtain regulatory approval of our vaccine candidates
3. 38We expect the vaccine candidates we develop will be regulated as biological products, or biologics, and therefore they may be subject to competition sooner than anticipated
4. 39Coverage and reimbursement may be limited or unavailable in certain market segments for our vaccine candidates, which could make it difficult for us to sell our vaccine candidates, if approved, profitably
5. 40Patients who receive vaccines generally rely on third-party payors to reimburse all or part of the associated costs. Obtaining coverage and adequate reimbursement from third-party payors is critical to new product acceptance
6. 41Healthcare legislative reform measures may have a negative impact on our business, financial condition, results of operations and prospects72% rewritten
7. 42measures, and, in some cases, policies to encourage importation from other countries (subject to federal approval) and bulk purchasing. The OBBBA will also reduce funds for Medicaid programs, which are administered by the statesNew
8. 43The development, review and approval of our product candidates are subject to the operational capacity, processes and resource levels of regulatory authorities, which may fluctuate over time and could delay or adversely affect our businessNew

Risks Related to Our Intellectual Property

1. 44If we are unable to obtain and maintain patent protection for our technology and products, or if the scope of the patent protection obtained is not sufficiently broad, we may not be able to compete effectively in our markets
2. 45If we fail to comply with our obligations under any license, collaboration or other agreements, we may be required to pay damages and could lose intellectual property rights that are necessary for developing and protecting our vaccine candidates
3. 46Obtaining and maintaining our patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements
4. 47Third-party claims or litigation alleging infringement of patents or other proprietary rights, or seeking to invalidate our patents or other proprietary rights, may delay or prevent the development, manufacturing and commercialization of our PCV candidates and any future vaccine candidate
5. 48We may become involved in lawsuits to protect or enforce our patents, the patents of our licensors or our other intellectual property rights, which could be expensive, time consuming and unsuccessful22% rewritten
6. 49Changes in U.S. patent law or the patent law of other countries or jurisdictions could diminish the value of patents in general, thereby impairing our ability to protect our products
7. 50Any trademarks we may obtain may be infringed or successfully challenged, resulting in harm to our business
8. 51We may not be able to protect our intellectual property rights throughout the world, which could impair our business
9. 52Our reliance on third parties requires us to share our trade secrets, which increases the possibility that a competitor will discover them or that our trade secrets will be misappropriated or disclosed
10. 53We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of their former employers or other third parties

Risks Related to Ownership of Our Common Stock

1. 54The price of our stock has been and may continue to be volatile, and the value of our common stock has and may continue to decline, any of which could result in substantial losses for investors
2. 55We do not intend to pay dividends on our common stock so any returns will be limited to the value of our stock
3. 56Expectations relating to environmental, social and governance programs may impose additional costs and expose us to new risks26% rewritten
4. 57Provisions in our corporate charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
5. 58Claims for indemnification by our directors and officers may reduce our available funds to satisfy successful third-party claims against us and may reduce the amount of money available to us
6. 59Such limitation of liability does not apply to liabilities arising under federal securities laws and does not affect the availability of equitable remedies such as injunctive relief or rescission
7. 60While we maintain directors’ and officers’ liability insurance, such insurance may not be adequate to cover all liabilities that we may incur, which may reduce our available funds to satisfy third-party claims and may adversely impact our cash position
8. 61These exclusive-forum provisions may limit a stockholder’s ability to bring a claim in a judicial forum that it finds favorable for disputes with us or our directors, officers or other employees, which may discourage these types of lawsuitsNew
9. 62Raising additional capital may cause dilution to our stockholders, restrict our operations or require us to relinquish rights to our technologies or vaccine candidates
10. 63Unstable market and economic conditions may have serious adverse consequences on our business, financial condition and stock price
11. 64Significant changes and volatility in trade policies could materially affect our business, financial condition, liquidity and results of operations, and stock priceNew
12. 65If we fail to maintain proper and effective internal control over financial reporting, our ability to produce accurate and timely consolidated financial statements could be impaired, investors may lose confidence in our financial reporting and the trading price of our common stock may decline
13. 66Our reported financial results may be adversely affected by changes in accounting principles generally accepted in the United States
14. 67Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud68% rewritten
15. 68disclosure controls and procedures or internal controls and procedures, no matter how well-conceived and operated, can provide only reasonable, not absolute, assurance that the objectives of the control system are metNew
16. 69If securities or industry analysts do not publish research or publish inaccurate or unfavorable research about our business, our stock price and trading volume could decline